New combo therapy aims to stop cervical cancer return

NCT ID NCT07167160

Recruiting now Disease control Sponsor: Women's Hospital School Of Medicine Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding the immunotherapy drug camrelizumab to standard chemotherapy can help prevent cervical cancer from coming back in patients whose cancer had spread to lymph nodes. About 59 participants will receive the combination after surgery. The main goal is to see how many remain cancer-free after three years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: camrelizumab combined with chemotherapy
What this could lead to: If successful, this could offer a more effective adjuvant treatment for cervical cancer patients with positive lymph nodes, potentially reducing the risk of recurrence.
What could go wrong: This is an early phase 2 trial with only 59 participants and no control group, so results may not be definitive. Side effects from immunotherapy and chemotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER IMMUNOCHEMOTHERAPY

Contacts and locations

Locations

Women's Hospital, School of Medicine, Zhejiang University
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.